Ascletis to Present Data on Multiple Programs at the American Diabetes Association's 2026 Scientific Sessions
HONG KONG, April 30, 2026 /PRNewswire/ — Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces today poster presentations highlighting multiple programs at the American Diabetes Association’s (ADA’s) 2026 Scientific Sessions, taking place June 5–8, 2026 in New Orleans, Louisiana. The presentations include a late breaking poster presentation on the preclinical data of ASC39, an eloralintide-like selective and […]



